Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 01NVF24306 | Other Grant/Funding Number | Federal Joint Committee (G-BA), Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Heinrich-Heine University, Duesseldorf | OTHER |
| inav - Institute for Applied Health Services Research GmbH, Berlin, Germany | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits.
Eligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU). The primary endpoint is favorable functional outcome at 90 days, defined as modified Rankin Scale (mRS) 0-2 or return to pre-stroke mRS. Endpoint assessment at 90 days is performed by blinded assessors (PROBE design).
Secondary outcomes include early neurological deterioration, recurrent stroke, delirium, mortality, health-related quality of life, healthcare utilization, and cost-effectiveness. A mixed-methods process evaluation examines feasibility, acceptability, and implementation aspects of the ambulatory care model.
Stroke unit treatment in Germany is currently organized as multi-day inpatient care regardless of stroke severity. However, a substantial proportion of patients with acute ischemic stroke or transient ischemic attack present with non-disabling or fully regressed neurological deficits and may not require prolonged inpatient monitoring. At the same time, demographic changes and increasing stroke incidence in older populations challenge inpatient stroke unit capacity and resource allocation.
International experience with structured outpatient TIA and minor stroke clinics suggests that ambulatory management models may provide comparable clinical safety while reducing hospital utilization. However, randomized evidence for such models within the German healthcare system is lacking.
The ARTIFICE trial evaluates a structured ambulatory stroke unit care model designed to provide comprehensive same-day multiprofessional assessment and initiation of secondary prevention while maintaining patient safety. The study investigates whether this ambulatory care approach can represent a medically safe and resource-efficient alternative to conventional inpatient stroke unit treatment in selected older patients.
In addition to clinical effectiveness, the study examines patient-reported outcomes, healthcare utilization, cost-effectiveness, and implementation aspects to inform future health services planning.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ambulatory Stroke Unit Care (aSU) | Experimental | Participants receive structured ambulatory stroke unit care consisting of comprehensive same-day multiprofessional assessment, diagnostic evaluation, and initiation of secondary prevention. After evaluation, clinically stable participants are discharged home with structured follow-up. |
|
| Inpatient Stroke Unit Care (SU) | Active Comparator | Participants receive guideline-based inpatient stroke unit treatment according to standard clinical practice, including monitoring and diagnostic evaluation during hospital admission. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ambulatory Stroke Unit Care | Other | Structured ambulatory stroke care model providing same-day neurological assessment, diagnostic work-up, therapeutic evaluation, and multidisciplinary case review, followed by discharge home if medically appropriate. |
| Measure | Description | Time Frame |
|---|---|---|
| Favorable Functional Outcome at 90 Days | Favorable functional outcome defined as modified Rankin Scale (mRS) score 0-2 or return to pre-stroke mRS level, assessed by blinded outcome assessors. | 90 days (±14 days) after randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Early Neurological Deterioration | Increase in National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points compared to baseline. | Within 7 days after randomization |
| Recurrent Stroke | Occurrence of recurrent ischemic stroke, hemorrhagic stroke, or transient ischemic attack during follow-up. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jan C Purrucker, Prof. Dr. | Contact | +49 6221 56 6999 | artifice.studie@med.uni-heidelberg.de |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Heidelberg University Hospital | Recruiting | Heidelberg | 69120 | Germany |
Individual participant data will not be made publicly available. De-identified data may be shared with qualified researchers upon reasonable request, subject to approval by the sponsor and in accordance with applicable data protection regulations (including GDPR), institutional policies, and a data use agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| D002546 | Ischemic Attack, Transient |
| D003693 | Delirium |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Participants aged ≥60 years with acute ischemic stroke, transient ischemic attack, or retinal ischemia and non-disabling neurological deficits are randomized 1:1 to ambulatory stroke unit care or guideline-based inpatient stroke unit care after confirmation that both treatment settings are medically feasible. Randomization is computer-generated, block-based, and stratified by baseline modified Rankin Scale (0-3 vs 4-5).
Not provided
Not provided
This is an open-label study due to the nature of the care setting. Outcome assessment at 90 days is performed by independent study personnel who are blinded to treatment allocation (PROBE design).
| Conventional Stroke Unit Care | Other | Standard inpatient stroke unit treatment according to national clinical guidelines, including hospital-based monitoring, diagnostic evaluation, and initiation of secondary prevention. |
|
| Up to 90 days after randomization (primary safety observation period) |
| Delirium Occurrence | Occurrence of delirium assessed using the Confusion Assessment Method (CAM). | Within 7 days after randomization |
| All-Cause Mortality | Death from any cause. | 90 days and 12 months after randomization |
| Functional Status | Change in Barthel Index score from baseline to 90 days. | Baseline and 90 days |
| Stroke Impact | Change in SIS-16 score from baseline to 90 days. | Baseline and 90 days |
| Mobility | Change in Timed Up and Go Test (TUG) time from baseline to 90 days. | Baseline and 90 days |
| Health-Related Quality of Life | Change in EQ-5D-5L index value and EQ visual analogue scale (EQ-VAS) from baseline to 90 days. | Baseline and 90 days |
| Healthcare Utilization | Use of outpatient, inpatient, and nursing care services assessed by questionnaire. | Up to 90 days after randomization |
| Serious Adverse Events | Occurrence of serious adverse events including unplanned hospitalization or death. | Up to 90 days after randomization |
| D009422 |
| Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D002545 | Brain Ischemia |
| D003221 | Confusion |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |